Although in previous studies, DCs were separately loaded with tumor lysates or suppressed for inhibitory immune checkpoints like PD-L1/PD-L2, however, there is no study regarding the concomitant silencing of CTLA-4 and tumor cell lysate loading on DCs in order to boost the effectiveness of DC-based immunotherapy. This evidence concerns the gene PDCD1LG2 and neoplasm.